ALBUVIRTIDE AGAINST COMMON TYPE COVID-19

ABSTRACT

To evaluate the safety and efficacy of albuvir-tide (ABT) in the treatment of patients with Corona-virus Disease 2019 (COVID-19). The study was conducted in 22 patients with laboratory-confirmed COVID-19 infections in the Public Health Clinical Center of Chengdu from February to April, 2020. All patients intravenously received 320 mg of ABT on Day 1, 2, 3, 8 in addition to standard care. The primary endpoint was a coronavirus-negative result and the pneumonia was alleviated in patients. It showed that the average age of the patients was 48.2 ± 18.0 years old, and 10 of them (45.5%) were male. The most common symptoms were cough (81.8%), expectoration (72.7%o), fever (27.3%), while no abnormal blood cell count was observed among these patients. The CT examination showed that 6 patients (27.3%) with unilateral pneumonia and 15 of them (68.2%) with bilateral pneumonia, confirmed by massive patchy shadows and ground glass opacities within patient lungs. After the ABT treatment, the cough, expectoration and fever were relieved by 33.3%, 43.8% and 100%, respectively. The mean body temperature recovery time was 2.5 days (range, 1-4 days). The alleviated pneumonia was seen in 14 patients (63.6%) by CT scanning after day 8. Based on nasopharyngeal sampling, the COVID-19 RNA was negatively detected in 14 of 22 patients after 8 days of ABT treatment. Meanwhile, no obvious adverse events occurred during and after treatment. The results showed that ABT presents a favorable clinical response in patients infected with COVID-19.